<DOC>
	<DOCNO>NCT00750659</DOCNO>
	<brief_summary>Current therapeutic result advance chronic myeloid leukemia ( CML ) Ph+ acute lymphoblastic leukemia ( ALL ) rather disappointing . Most patient eventually undergo allogeneic stem cell transplantation . Nilotinib novel TKI tyrosine kinase inhibitor 30 fold potency Imatinib . Based previous preliminary experience author rationalize Nilotinib therapy pre- allogeneic transplantation patient advance CML Ph+ALL reduce tumor mass pre- transplant achieve state minimal residual disease ( MRD ) therefore may improve transplantation outcome without increase toxicity . In addition allow time improve patient medical condition find unrelated donor enable allogeneic transplantation , induce anti tumor effect post PBSC w\o DLI ( donor lymphocyte infusion )</brief_summary>
	<brief_title>Nilotinib Pre Post Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Patients Ph+ advance CML ( &gt; CR1 ) Ph+ALL . 2 . Hematological , Cytogenetic ( Ph+ ) and/or BCR/ABL positive document diagnosis CML Ph+ALL pre alloSCT . 3 . Patients age 1865 year age . 4 . .Patients must HLA compatible donor willing capable donate peripheral blood stem cell ( first choice ) bone marrow progenitor cell use conventional technique , blood lymphocyte indicate ( HLA compatible define 5/6 6/6 match relate matched unrelated donor . 5 . Adequate end organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL , creatinine &lt; 1.5 x ULN 6 . Patient must LVEF &gt; 45 % prior entry study . 7 . Patient must QTc &lt; 450 msec study entry . 8 . Lung diffusion capacity ( DLCO &gt; 40 % predict ) 9 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . 10 . Written , voluntary inform consent . 1 . Patients CML first chronic phase 2 . Patient receive investigational agent within 28 day first day study drug dosing , unless disease rapidly progress . 3 . ECOG performance status &gt; 2 4 . Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 5 . Impaired cardiac function include one following : LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine echocardiogram Inability determine QT interval ECG Complete leave bundle branch block Long QT syndrome know family history long QT syndrome . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc Myocardial infarction within 12 month prior start study Other clinically significant heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) . 6 . Female patient pregnant breastfeeding . 7 . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . 8 . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 9 . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . 10 . Patient major surgery within 2 week prior study entry . 11 . Patient significant history noncompliance medical regimen inability grant reliable informed consent . 12 . Patients active CNS disease ( patient history CNS disease allow ) . 13 . Patients pleural effusion ascites 14 . Patients history pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Ph+ acute lymphoblastic leukemia</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>nilotinib</keyword>
</DOC>